Development of ACRODAT®, a new software medical device to assess disease activity in patients with acromegaly.

about

Growth Hormone Research Society perspective on biomarkers of GH action in children and adults.

P2860

Q52684487-9E2AF7EB-7E05-4579-AA1B-8559BDB14269

P2860

Development of ACRODAT®, a new software medical device to assess disease activity in patients with acromegaly.

Item

http://www.wikidata.org/entity/Q47130943

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Development of ACRODAT®, a new ...... y in patients with acromegaly.

@en

Development of ACRODAT®, a new ...... y in patients with acromegaly.

@nl

type

Item

label

Development of ACRODAT®, a new ...... y in patients with acromegaly.

@en

Development of ACRODAT®, a new ...... y in patients with acromegaly.

@nl

prefLabel

Development of ACRODAT®, a new ...... y in patients with acromegaly.

@en

Development of ACRODAT®, a new ...... y in patients with acromegaly.

@nl

P1476

Development of ACRODAT®, a new ...... ty in patients with acromegaly

@en

P2093

Andreas Pleil

http://www.w3.org/2001/XMLSchema#string

Anton Luger

http://www.w3.org/2001/XMLSchema#string

Christian J Strasburger

http://www.w3.org/2001/XMLSchema#string

David Clemmons

http://www.w3.org/2001/XMLSchema#string

Joli van der Lans-Bussemaker

http://www.w3.org/2001/XMLSchema#string

Xavier Badia

http://www.w3.org/2001/XMLSchema#string

P2860

Endoscopic vs microsurgical transsphenoidal surgery for acromegaly: outcomes in a concurrent series of patients using modern criteria for remission.

Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension

Expert consensus document: A consensus on the medical treatment of acromegaly.

A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly.

SAGIT®: clinician-reported outcome instrument for managing acromegaly in clinical practice--development and results from a pilot study

Pasireotide versus octreotide in acromegaly: a head-to-head superiority study.

Place of cabergoline in acromegaly: a meta-analysis.

Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY.

Acromegaly incidence, prevalence, complications and long-term prognosis: a nationwide cohort study.

Conventional and novel biomarkers of treatment outcome in patients with acromegaly: discordant results after somatostatin analog treatment compared with surgery.

P2888

s11102-017-0835-5

P304

692-701

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11102-017-0835-5

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Susan M Webb

Jens Otto Lunde Jørgensen

P577

2017-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28887782

http://www.w3.org/2001/XMLSchema#string

P932

5655576

http://www.w3.org/2001/XMLSchema#string

Development of ACRODAT®, a new software medical device to assess disease activity in patients with acromegaly.

about

P2860

P2860

Development of ACRODAT®, a new software medical device to assess disease activity in patients with acromegaly.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P932